Contract Manufacturers Will Be Subject to More Inspections in U.S. and EU
This article was originally published in The Gold Sheet
Executive Summary
Contract manufacturing organizations will face more scrutiny from regulators and pharmaceutical manufacturers in the U.S. and the EU under pending supply chain initiatives. With the growing use of outsourcing, manufacturers have to be careful about who they choose as CMOs.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.